A prospective observational study of Active surveillance in primary desmoid fibromatosis

医学 危险系数 比例危险模型 内科学 临床终点 纤维瘤病 前瞻性队列研究 侵袭性纤维瘤病 观察研究 原发性肿瘤 无进展生存期 外科
作者
Chiara Colombo,Marco Fiore,Giovanni Grignani,Francesco Tolomeo,Alessandra Merlini,Elena Palassini,Paola Collini,Silvia Stacchiotti,Paolo G. Casali,Federica Perrone,Luigi Mariani,Ugo Pastorino
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
标识
DOI:10.1158/1078-0432.ccr-21-4205
摘要

To prospectively assess the behaviour of primary sporadic (not FAP associated) desmoid fibromatosis (DF) managed by active surveillance (AS).This is an Italian prospective, multicenter, observational study (NCT02547831) including patients {greater than or equal to}16 years with primary sporadic DF at any site. Patients were assessed by Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 . Primary end-point was progression-free survival (PFS) at 3 years. Treatment-free survival (TFS) was also analyzed. PFS and TFS were calculated by Kaplan-Meier plots and compared by log-rank test Cox proportional-hazard multivariable regression analyses were performed.From 2013 to 2018 108 consecutive patients were included (82% female); median age was 39-yr; median size was 51 mm. CTNNB1 mutations were: T41A (50%); S45F (12%); other (19%); WT (19%). At 32.3-month median-FU, 42/108 (39%) showed RECIST progression. Spontaneous regression (SR) was initially observed in 27/108 (25%), while it followed dimensional progression in other 33/108 (31%). PFS at 36 months was 54.5% (95% CI, 44.9%-66.1%). Thirty-five/108 (32%) patients received active treatments, 18/108 (17%) after RECIST progression and 17/108 (15%) after symptomatic progression. TFS at 36 months was 65.9% (95% CI, 57.3%-75.9%). Larger tumor size and extremity location were associated to shorter TFS and a trend for S45F mutation was also observed (p=0.06), while none of the above variables was significantly associated to PFS.In primary DF, AS can be proposed, since disease stabilization and SR frequently occur. However extra care should be taken for patients with tumors of larger size, extremity location and S45F mutation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SciGPT应助姒嵛采纳,获得10
2秒前
隐形静芙完成签到 ,获得积分10
13秒前
cqcqcq完成签到 ,获得积分10
14秒前
oooo发布了新的文献求助10
15秒前
小小完成签到,获得积分10
15秒前
19秒前
咿咿呀呀完成签到,获得积分10
22秒前
小小发布了新的文献求助10
25秒前
发nature完成签到,获得积分10
26秒前
袁方正完成签到,获得积分10
27秒前
寒冷的奇异果完成签到,获得积分10
29秒前
30秒前
自然白风完成签到,获得积分10
34秒前
cotton123发布了新的文献求助10
35秒前
35秒前
Kyone完成签到,获得积分10
36秒前
小蘑菇应助追风采纳,获得10
39秒前
任世界灯火阑珊完成签到,获得积分10
39秒前
微笑发布了新的文献求助10
40秒前
田様应助火星上的安波采纳,获得10
40秒前
现代的紫霜完成签到,获得积分10
40秒前
姒嵛完成签到 ,获得积分10
44秒前
Aaron完成签到,获得积分10
46秒前
学术通zzz发布了新的文献求助10
46秒前
可能可能最可能不像不像不太像完成签到 ,获得积分10
46秒前
聂青枫完成签到,获得积分10
48秒前
49秒前
51秒前
52秒前
52秒前
54秒前
巫郁发布了新的文献求助30
56秒前
lincy发布了新的文献求助10
56秒前
58秒前
59秒前
1分钟前
西风惊绿完成签到,获得积分10
1分钟前
1分钟前
1分钟前
包容丹云完成签到,获得积分10
1分钟前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 3000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
Maneuvering of a Damaged Navy Combatant 650
Mixing the elements of mass customisation 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3777918
求助须知:如何正确求助?哪些是违规求助? 3323535
关于积分的说明 10214760
捐赠科研通 3038695
什么是DOI,文献DOI怎么找? 1667611
邀请新用户注册赠送积分活动 798220
科研通“疑难数据库(出版商)”最低求助积分说明 758315